Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celldex To Fly Solo With Phase III Trial Of Brain Cancer Vaccine

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

All on its own, Celldex is gearing up to run a Phase III trial in the second half of 2011, testing its therapeutic cancer vaccine rindopepimut in newly diagnosed glioblastoma, after releasing positive results from ACT III, the last of three trials in its Phase II program.
Advertisement

Related Content

Faster FDA Review A Possibility For Celldex’s Rintega After Phase II
Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
Celldex Differentiated Immuno-Oncology Asset Ripe For Combos
Exelixis Slashes Staff Again, Focuses All Internal Development on XL184
R&D Realities Disturb Dreams About Orphan Brain Cancer Blockbusters
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch
Pfizer Axes Deal For Brain Cancer Vaccine, Leaves Partner Celldex In the Lurch

Topics

Advertisement
UsernamePublicRestriction

Register

PS004610

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel